This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
Glaucoma Research Foundation Shaffer Grants present a unique opportunity for investigators to pursue innovative ideas in the spirit of high risk/high reward scientific discovery.
ARVO is the annual meeting of the Association for Research in Vision and Ophthalmology.
“Whatever curves life throws at us, I believe one must always make the best out of a situation; there is always a positive side.”
– Niki De Lara
Rhopressa 0.02% is a novel once-daily eye drop for lowering elevated intraocular pressure.
Generic drugs work well for most patients, but there are differences compared to the brand name products.
Concerns about driving often come up with glaucoma and may be brought to the doctor’s attention by the patient or a family member.
Glaucoma is a complex disease resulting from a mix of genetic and environmental factors. Family history is an important risk factor for glaucoma.
What will your new doctor need to know to take over management and treatment of your glaucoma?
Laser refractive surgery is not prohibited for glaucoma suspects or glaucoma patients. With multiple choices now available for refractive correction, both patients and physicians have more options.
James D. Brandt, MD co-moderated the session “New Horizons in Glaucoma Drug Delivery” with Anne L. Coleman, MD, PhD at the 7th annual Glaucoma 360 New Horizons Forum in San Francisco.
An introduction to Endoscopic Cyclophotocoagulation (ECP) for treating glaucoma.
Biomarkers can provide physicians with better tools to diagnose and manage glaucoma before vision is lost, as well as accelerate better treatments for glaucoma.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.
Print Subscription
We will mail Gleams anywhere in the United States and Canada, but we do not mail internationally. Please sign up for the email edition if you live outside of the US or Canada.
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
E-mail Subscription
You can unsubscribe at any time. GRF will not share your personal information with any other organizations. Please see our Privacy Policy for further information.
